European Union Drugs Agency. (2026) Drug production in Afghanistan and the region: innovative monitoring to better inform policy. Luxembourg: Publications Office of the European Union.

European Union Drugs Agency. (2026) Frequently asked questions (FAQ): drug-induced deaths in Europe.

European Union Drugs Agency. (2026) Assessment of the threat posed by highly potent synthetic opioids in Europe. Luxembourg: Publications Office of the European Union.

European Union Drugs Agency. (2026) The future of synthetic drugs 2050: scenarios for Europe. Lisbon: EUDA.

European Union Drugs Agency. (2026) EUDA initial report on the new psychoactive substance: 3-(3-{1-[1-(4-chlorophenyl)ethyl]piperidin-4-yl}-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-1-yl)propanenitrile (cychlorphine), in accordance with Article 9 of Regulation (EU) 2023/1322. Luxembourg: Publications Office of the European Union.

European Union Drugs Agency. (2026) EUDA initial report on the new psychoactive substance: 8-[1-(4-chlorophenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (spirochlorphine), in accordance with Article 9 of Regulation (EU) 2023/1322,. Luxembourg: Publications Office of the European Union.

European Union Drugs Agency. (2026) European drug report 2026: trends and developments. Lisbon: EUDA.

European Union Drugs Agency. (2026) Data from the European Syringe Collection and Analysis Project Enterprise (ESCAPE): data explorer, analysis and key 2024 findings. Lisbon: EUDA.

European Union Drugs Agency. (2026) Cannabis – the current situation in Europe (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency, DEVIDA. (2026) Cocaine and the environment: building the foundations for measurement. Luxembourg: Publications Office of the European Union. 10.2810/8541104.

European Union Drugs Agency. (2026) Cocaine – the current situation in Europe (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) Consolidated annual activity report 2025 – key achievements and governance: a year in review. Lisbon: EUDA. DOI: 10.2810/7644215.

European Union Drugs Agency. (2026) Drug supply, production and precursors – the current situation in Europe (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) EUDA statistical bulletin - data and statistics on the drug situation in Europe. [EUDA]

European Union Drugs Agency. (2026) Heroin and other opioids – the current situation in Europe (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) MDMA – the current situation in Europe (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) New psychoactive substances – the current situation in Europe (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) Opioid agonist treatment – the current situation in Europe (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) Other drugs – the current situation in Europe (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) Synthetic stimulants – the current situation in Europe (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) Understanding Europe’s drug situation in 2026 – key developments (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) Dual disorders: health and social responses.

European Union Drugs Agency. (2026) Cannabis laws in Europe.

European Union Drugs Agency. (2026) Wastewater analysis and drugs — a European multi-city study. Lisbon: European Drugs Agency.

European Union Drugs Agency. (2026) Drug-related infectious diseases toolkit.

European Union Drugs Agency. (2026) Frequently asked questions (FAQ): gender and drugs in Europe.

European Union Drugs Agency. (2026) Ketamine in Europe: EMPACT situation report. Luxembourg: Publications Office of the European Union.

European Union Drugs Agency. (2026) Precursor assessment report of 4’-chloropropiophenone. Lisbon: EUDA.

European Union Drugs Agency. (2026) Precursor assessment report of phenyl-2-nitropropene. Lisbon: EUDA.

European Union Drugs Agency. (2026) Precursor assessment report of 2-bromo-3′-chloropropiophenone. Lisbon: EUDA.

European Union Drugs Agency. (2026) Precursor assessment report of 2-bromo-3′-methylpropiophenone. Lisbon: EUDA.

European Union Drugs Agency. (2026) Precursor assessment report of 2-bromo-4′-chloropropiophenone. Lisbon: EUDA.

European Union Drugs Agency. (2026) Precursor assessment report of 2-bromo-4′-methylpropiophenone. Lisbon: EUDA.

European Union Drugs Agency. (2026) Precursor assessment report of 3′-chloropropiophenone. Lisbon: EUDA.

European Union Drugs Agency. (2026) Precursor assessment report of 3′-methylpropiophenone. Lisbon: EUDA.

European Union Drugs Agency. (2026) Precursor assessment report of 4′-methylpropiophenone. Lisbon: EUDA.

European Union Drugs Agency. (2026) EUDA Single programming document 2026-2028. Lisbon: EUDA. DOI: 10.2810/1951740.

European Union Drugs Agency, Euro-Den Plus. (2026) Euro-DEN Plus: The European Drug Emergencies Network Plus Protocol. Lisbon: EUDA.

European Union Drugs Agency. (2026) Reitox Alliance operating framework. Lisbon: EUDA.

European Union Drugs Agency. (2026) Drug-induced deaths – the current situation in Europe (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) Drug-related infectious diseases – the current situation in Europe (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) Drug-related infectious diseases.

European Union Drugs Agency. (2026) Harm reduction – the current situation in Europe (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) Injecting drug use in Europe – the current situation (European drug report 2026). Lisbon: EUDA.

European Union Drugs Agency. (2026) The Reitox network: frequently asked questions.

European Union Drugs Agency. (2025) EUDA webinar recording: Novel approaches to prevent the recruitment and participation of young people in European drug markets. EUDA.

European Union Drugs Agency. (2025) Collection of drug-related hospital emergency data in Western Balkans and Southern Neighbourhood countries using Euro-DEN Plus methodology. Technical report. Luxembourg: Publications Office of the European Union.

European Union Drugs Agency. (2025) Drug policy evaluation in Europe — topic overview.

European Union Drugs Agency. (2025) European Drug Emergencies Network (Euro-DEN Plus): data and analysis.

[European Union Drugs Agency] New threat assessment system launched to strengthen Europe’s response to drug-related threats. (26 Nov 2025)

European Union Drugs Agency. (2025) Drug-related violence hub page.

European Union Drugs Agency. (2025) How to run a trends workshop: an EMCDDA foresight toolkit for the drugs field. Lisbon: EUDA.

European Union Drugs Agency. (2025) EUDA communication strategy 2025-2028: a customer-first approach. Luxembourg: Publications Office of the European Union. 10.2810/1209755.

European Union Drugs Agency. (2025) EUDA International Cooperation Framework. Lisbon: EUDA.

European Union Drugs Agency. (2025) European toolkit for the elimination of viral hepatitis in prisons (EuroHePP). Lisbon: EUDA.

European Union Drugs Agency. (2025) Viral hepatitis elimination barometer among people who inject drugs in Europe.

European Union Drugs Agency. (2025) Health and social responses: provision of harm reduction equipment for high-risk drug use.

European Union Drugs Agency. (2025) Viral hepatitis elimination barometer among people who inject drugs — European overview.

European Union Drugs Agency. (2025) Assessing the threat posed by the increased availability, use and harms of highly potent synthetic opioids in the Baltic region. Lisbon: EUDA.

European Union Drugs Agency. (2025) Dashboard: Prevalence of cocaine use in Europe. [EUDA]

European Union Drugs Agency. (2025) Drug supply, production and precursors – the current situation in Europe (European Drug Report 2025). Lisbon: EUDA.

European Union Drugs Agency. (2025) Drug-induced deaths – the current situation in Europe (European Drug Report 2025). Lisbon: EUDA.

European Union Drugs Agency. (2025) Drug-related infectious diseases – the current situation in Europe (European Drug Report 2025). Lisbon: EUDA.

European Union Drugs Agency. (2025) EUDA initial report on the new psychoactive substance 2-methylmethcathinone (2-MMC). Lisbon: EUDA.

European Union Drugs Agency. (2025) EUDA initial report on the new psychoactive substance 4-bromomethcathinone (4-BMC). Lisbon: EUDA.

European Union Drugs Agency. (2025) EUDA initial report on the new psychoactive substance N-ethylnorpentedrone (NEP). Lisbon: EUDA.

European Union Drugs Agency. (2025) European drug report 2025: trends and developments. Lisbon: European Union Drugs Agency.

European Union Drugs Agency. (2025) Harm reduction – the current situation in Europe (European Drug Report 2025). Lisbon: EUDA.

European Union Drugs Agency. (2025) Heroin and other opioids – the current situation in Europe (European Drug Report 2025). Lisbon: EUDA.

European Union Drugs Agency. (2025) MDMA – the current situation in Europe (European Drug Report 2025). Lisbon: EUDA.

European Union Drugs Agency. (2025) New psychoactive substances – the current situation in Europe (European Drug Report 2025). Lisbon: EUDA.

European Union Drugs Agency. (2025) Other drugs – the current situation in Europe (European Drug Report 2025). Lisbon: EUDA.

European Union Drugs Agency. (2025) Understanding Europe’s drug situation in 2024 – key developments (European Drug Report 2025). Lisbon: EUDA.

European Union Drugs Agency. (2025) EUDA Consolidated annual activity report 2024 – key achievements and governance: a year in review. Luxembourg: Publications Office of the European Union.

European Union Drugs Agency. (2025) EU drug market: MDMA.

European Union Drugs Agency. (2025) Wastewater analysis and drugs — a European multi-city study.

European Union Drugs Agency. (2025) European web survey on drugs (EWSD) 2024.

European Union Drugs Agency. (2025) European Web Survey on Drugs 2024: top-level findings, 24 EU countries and Norway. Lisbon: European Union Drugs Agency.

European Union Drugs Agency. (2025) Prevention topics overview.

European Union Drugs Agency. (2025) Synthetic cannabinoids.

European Union Drugs Agency. (2024) EUDA webinar: Responses for drugs in prisons — implications for Latin America, Caribbean and Europe. EUDA.

European Union Drugs Agency. A new network of forensic and toxicology laboratories to strengthen EU preparedness on drugs. (12 Nov 2024)

European Union Drugs Agency, Robert Koch Institut. (2024) Drug-related infectious diseases (DRID) technical protocol – surveys on HIV and viral hepatitis in people who inject drugs. Lisbon: EUDA.

European Union Drugs Agency, Society for the Study of Addiction. (2024) Official LxAddictions podcast. In cooperation with the Society for the Study of Addiction (SSA). Lisbon: EUDA.

European Union Drugs Agency. (2024) The impact of economic recessions on the use of illicit drugs: findings from a scoping literature review. Luxembourg: Publications Office of the European Union.

European Union Drugs Agency. (2024) Penalties for drug law offences in Europe at a glance.

European Union Drugs Agency. (2024) Topic overview: penalties at a glance.

European Union Drugs Agency. (2024) Frequently asked questions (FAQ): therapeutic use of psychedelic substances.

European Union Drugs Agency. (2024) Drug supply, production and precursors – the current situation in Europe (European Drug Report 2024). Lisbon: EUDA.

European Union Drugs Agency. (2024) Drug-induced deaths – the current situation in Europe (European Drug Report 2024). Lisbon: EUDA.

European Union Drugs Agency. (2024) Drug-related infectious diseases – the current situation in Europe (European Drug Report 2024). Lisbon: EUDA.

European Union Drugs Agency. (2024) Harm reduction – the current situation in Europe (European Drug Report 2024). Lisbon: EUDA.

European Union Drugs Agency. (2024) MDMA – the current situation in Europe (European Drug Report 2024). Lisbon: EUDA.

European Union Drugs Agency. (2024) New psychoactive substances – the current situation in Europe (European Drug Report 2024). Lisbon: EUDA.

European Union Drugs Agency. (2024) Other drugs – the current situation in Europe (European Drug Report 2024). Lisbon: EUDA.

European Union Drugs Agency. (2024) Understanding Europe’s drug situation in 2024 – key developments (European Drug Report 2024). Lisbon: EUDA.